Dexfenfluramine, brand name Redux had been showered with lawsuits accusing it to yield severe side effects. Dexfenfluramine was manufactured by American Home Products Corp and was marketed with brand name Redux.

Redux (dexfenfluramine) is an oral medication. It is used for treatment of obesity. It belongs to serotonin reuptake inhibitor and releasing agent group of drugs. Redux is actually dexfenfluramine hydrochloride. It is administered with low calorie diet for weight reduction and management. It was approved by U.S. Food and Drug administration in 1990 to be used for weight loss. Later it was linked with several cardio vascular diseases including primary pulmonary hypertension. FDA cancelled its approval in 1997, due to safety concerns. It was approved as an appetite suppressant in the obesity management by FDA.

Dexfenfluramine constituted Fen part of popular diet drug Fen-Phen. Fen-Phen was a combination of Pondimin (Fenfluramine) or Redux (Dexfenfluramine) with phentermine. All these drugs were used for treatment of obesity. The combination drug Fen-Phen was introduced as a miracle drug for weight loss. Both Redux (dexfenfluramine) and Pondimin (fenfluramine) were weight loss drugs and were manufactured by American Home Products (“AHP”). They were appetite suppressant and were administered with low calorie diet for short term for weight management.

These drugs acted by changing the levels of serotonin in the brain. Both of these drugs were withdrawn from the market in September of 1997 after being linked to serious cardiac valvular disease, and primary pulmonary hypertension.

Use of Dexfenfluramine was linked to Pulmonary Hypertension. It is a fatal side effect. Dexfenfluramine overdose was also linked to Tachycardia, convulsions, restlessness or excitement and ventricular arrhythmia. The most severe side effect of this drug is the development of valvular heart disease. It could result into primarily aortic regurgitation, hypertension, angina pectoris, palpitation, vasodilation and migraine.

Different studies also revealed the same fact. Withdrawal of Dexfenfluramine by FDA proved that it is a dangerous drug. This led to several lawsuits being filed against American Home Products Corp related to Dexfenfluramine side effects. Mayo clinic also reported 24 cases of heart valve disease in patients.

Another study concluded that one third of 291 patients treated with Pondimin or Redux showed abnormal echocardiograms. 20 of the 291 patients were administered with Redux or a combination of Redux and phentermine. Six out of twenty patients had abnormal echocardiograms. Out of these six patients, two patients were given Redux alone.

These facts have trigged several lawsuits against American Home Products Corp, related to dexfenfluramine. After Redux was withdrawn from the market, the lawsuits flooded in alleging Wyeth-Ayerst Laboratories of hiding the risk of cardiovascular risks associated with the drug. In 1999, the company came forward for settlement and put aside $3.75 billion to settle individual claims related to damages caused by use of Dexfenfluramine over the next 15 years.

American Home Products was blamed of hiding the risks associated with this drug even it had knowledge of the research and adverse drug experience reports on Dexfenfluramine. It did not warn patients adequately and played with lives of many.  After FDA intervened American Home Products pulled out the drug from the market. At the time of withdrawal of Dexfenfluramine millions of people had already taken the drug and had suffered due to its side effects.